|
1
|
Shay JW and Wright WE: Telomeres and
telomerase: Three decades of progress. Nat Rev Genet. 20:299–309.
2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Roake CM and Artandi SE: Regulation of
human telomerase in homeostasis and disease. Nat Rev Mol Cell Biol.
21:384–397. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Barthel FP, Wei W, Tang M,
Martinez-Ledesma E, Hu X, Amin SB, Akdemir KC, Seth S, Song X, Wang
Q, et al: Systematic analysis of telomere length and somatic
alterations in 31 cancer types. Nat Genet. 49:349–357.
2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Maciejowski J and de Lange T: Telomeres in
cancer: Tumour suppression and genome instability. Nat Rev Mol Cell
Biol. 18:175–186. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Cukusić A, Skrobot Vidacek N, Sopta M and
Rubelj I: Telomerase regulation at the crossroads of cell fate.
Cytogenet Genome Res. 122:263–272. 2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pestana A, Vinagre J, Sobrinho-Simões M
and Soares P: TERT biology and function in cancer: Beyond
immortalisation. J Mol Endocrinol. 58:R129–R146. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Colebatch AJ, Dobrovic A and Cooper WA:
TERT gene: Its function and dysregulation in cancer. J Clin Pathol.
72:281–284. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin
L and Garraway LA: Highly recurrent TERT promoter mutations in
human melanoma. Science. 339:957–959. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Peifer M, Hertwig F, Roels F, Dreidax D,
Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann
JM, et al: Telomerase activation by genomic rearrangements in
high-risk neuroblastoma. Nature. 526:700–704. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lewis KA and Tollefsbol TO: Regulation of
the telomerase reverse transcriptase subunit through epigenetic
mechanisms. Front Genet. 7(83)2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Dogan F and Forsyth NR: Telomerase
regulation: A role for epigenetics. Cancers (Basel).
13(1213)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lee DD, Leão R, Komosa M, Gallo M, Zhang
CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolónio JD, et al: DNA
hypermethylation within TERT promoter upregulates TERT expression
in cancer. J Clin Invest. 129:223–229. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Renaud S, Loukinov D, Bosman FT,
Lobanenkov V and Benhattar J: CTCF binds the proximal exonic region
of hTERT and inhibits its transcription. Nucleic Acids Res.
33:6850–6860. 2005.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Li C, Liang Y, Wu M, Xu L and Cai W:
Telomerase activity analysis of esophageal carcinoma using
microdissection-TRAP assay. Chin Med J (Engl). 115:1405–1408.
2002.PubMed/NCBI
|
|
16
|
Yu HP, Xu SQ, Lu WH, Li YY, Li F, Wang XL
and Su YH: Telomerase activity and expression of telomerase genes
in squamous dysplasia and squamous cell carcinoma of the esophagus.
J Surg Oncol. 86:99–104. 2004.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Koyanagi K, Ozawa S, Ando N, Mukai M,
Kitagawa Y, Ueda M and Kitajima M: Telomerase activity as an
indicator of malignant potential in iodine-nonreactive lesions of
the esophagus. Cancer. 88:1524–1529. 2000.PubMed/NCBI
|
|
18
|
Inai M, Kano M, Shimada Y, Sakurai T,
Chiba T and Imamura M: Telomerase activity of the Lugol-stained and
-unstained squamous epithelia in the process of oesophageal
carcinogenesis. Br J Cancer. 85:1006–1013. 2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Clément G, Braunschweig R, Pasquier N,
Bosman FT and Benhattar J: Methylation of APC, TIMP3, and TERT: A
new predictive marker to distinguish Barrett's oesophagus patients
at risk for malignant transformation. J Pathol. 208:100–107.
2006.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Suzuki K, Kashimura H, Ohkawa J, Itabashi
M, Watanabe T, Sawahata T, Nakahara A, Muto H and Tanaka N:
Expression of human telomerase catalytic subunit gene in cancerous
and precancerous gastric conditions. J Gastroenterol Hepatol.
15:744–751. 2000.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wang Z, Xu J, Geng X and Zhang W: Analysis
of DNA methylation status of the promoter of human telomerase
reverse transcriptase in gastric carcinogenesis. Arch Med Res.
41:1–6. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Duarte MC, Babeto E, Leite KR, Miyazaki K,
Borim AA, Rahal P and Silva AE: Expression of TERT in precancerous
gastric lesions compared to gastric cancer. Braz J Med Biol Res.
44:100–104. 2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Silva TC, Leal MF, Calcagno DQ, de Souza
CR, Khayat AS, dos Santos NP, Montenegro RC, Rabenhorst SH,
Nascimento MQ, Assumpção PP, et al: hTERT, MYC and TP53
deregulation in gastric preneoplastic lesions. BMC Gastroenterol.
12(85)2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hu H, Zhang Y, Zou M, Yang S and Liang XQ:
Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is
associated with telomere shortening and may contribute to
multistage carcinogenesis of gastric cancer. J Cancer Res Clin
Oncol. 136:1407–1414. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kanamaru T, Tanaka K, Kotani J, Ueno K,
Yamamoto M, Idei Y, Hisatomi H and Takeyama Y: Telomerase activity
and hTERT mRNA in development and progression of adenoma to
colorectal cancer. Int J Mol Med. 10:205–210. 2002.PubMed/NCBI
|
|
26
|
Choi JY, Yoon H, Na G, Choi YJ, Shin CM,
Park YS, Kim N and Lee DH: Evaluation of the expression of the
inhibitor of apoptosis protein family and human telomerase reverse
transcriptase in patients with advanced colorectal adenoma. J
Cancer Prev. 22:98–102. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Saleh S, Lam AK and Ho YH: Real-time PCR
quantification of human telomerase reverse transcriptase (hTERT) in
colorectal cancer. Pathology. 40:25–30. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Riegert-Johnson DL, Boardman LA, Crook JE,
Thomas CS, Johnson RA and Roberts ME: Shorter peripheral blood
telomeres are a potential biomarker for patients with advanced
colorectal adenomas. Int J Biol Markers. 27:e375–e380.
2012.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Roger L, Jones RE, Heppel NH, Williams GT,
Sampson JR and Baird DM: Extensive telomere erosion in the
initiation of colorectal adenomas and its association with
chromosomal instability. J Natl Cancer Inst. 105:1202–1211.
2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hardikar S, Burnett-Hartman AN, Phipps AI,
Upton MP, Zhu LC and Newcomb PA: Telomere length differences
between colorectal polyp subtypes: A colonoscopy-based case-control
study. BMC Cancer. 18(513)2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Nault JC, Calderaro J, Di Tommaso L,
Balabaud C, Zafrani ES, Bioulac-Sage P, Roncalli M and Zucman-Rossi
J: Telomerase reverse transcriptase promoter mutation is an early
somatic genetic alteration in the transformation of premalignant
nodules in hepatocellular carcinoma on cirrhosis. Hepatology.
60:1983–1992. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Nault JC, Mallet M, Pilati C, Calderaro J,
Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C and
Zucman-Rossi J: High frequency of telomerase reverse-transcriptase
promoter somatic mutations in hepatocellular carcinoma and
preneoplastic lesions. Nat Commun. 4(2218)2013.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Matsuda Y, Ishiwata T, Izumiyama-Shimomura
N, Hamayasu H, Fujiwara M, Tomita K, Hiraishi N, Nakamura K,
Ishikawa N, Aida J, et al: Gradual telomere shortening and
increasing chromosomal instability among PanIN grades and normal
ductal epithelia with and without cancer in the pancreas. PLoS One.
10(e0117575)2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Shimonishi T, Sasaki M and Nakanuma Y:
Precancerous lesions of intrahepatic cholangiocarcinoma. J
Hepatobiliary Pancreat Surg. 7:542–550. 2000.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hansel DE, Meeker AK, Hicks J, De Marzo
AM, Lillemoe KD, Schulick R, Hruban RH, Maitra A and Argani P:
Telomere length variation in biliary tract metaplasia, dysplasia,
and carcinoma. Mod Pathol. 19:772–779. 2006.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Aoki Y, Aida J, Kawano Y, Nakamura KI,
Izumiyama-Shimomura N, Ishikawa N, Arai T, Nakamura Y, Taniai N,
Uchida E, et al: Telomere length of gallbladder epithelium is
shortened in patients with congenital biliary dilatation:
Measurement by quantitative fluorescence in situ hybridization. J
Gastroenterol. 53:291–301. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ichikawa Y, Kamiyama M, Sekido H, Ishikawa
T, Miura Y, Kamiya N, Morita T and Shimada H: Telomerase activity
and Bcl-2 expression in gallbladders of pancreaticobiliary
maljunction patients: A preliminary study. J Hepatobiliary Pancreat
Surg. 11:34–39. 2004.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ishizumi T, McWilliams A, MacAulay C,
Gazdar A and Lam S: Natural history of bronchial preinvasive
lesions. Cancer Metastasis Rev. 29:5–14. 2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Greenberg AK, Yee H and Rom WN:
Preneoplastic lesions of the lung. Respir Res. 3(20)2002.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Lantuejoul S, Soria JC, Morat L, Lorimier
P, Moro-Sibilot D, Sabatier L, Brambilla C and Brambilla E:
Telomere shortening and telomerase reverse transcriptase expression
in preinvasive bronchial lesions. Clin Cancer Res. 11:2074–2082.
2005.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Lantuejoul S, Raynaud C, Salameire D,
Gazzeri S, Moro-Sibilot D, Soria JC, Brambilla C and Brambilla E:
Telomere maintenance and DNA damage responses during lung
carcinogenesis. Clin Cancer Res. 16:2979–2988. 2010.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Kang JU, Koo SH, Kwon KC, Park JW and Kim
JM: Gain at chromosomal region 5p15.33, containing TERT, is the
most frequent genetic event in early stages of non-small cell lung
cancer. Cancer Genet Cytogenet. 182:1–11. 2008.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Raynaud CM, Hernandez J, Llorca FP,
Nuciforo P, Mathieu MC, Commo F, Delaloge S, Sabatier L, André F
and Soria JC: DNA damage repair and telomere length in normal
breast, preneoplastic lesions, and invasive cancer. Am J Clin
Oncol. 33:341–345. 2010.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Heaphy CM, Bisoffi M, Joste NE,
Baumgartner KB, Baumgartner RN and Griffith JK: Genomic instability
demonstrates similarity between DCIS and invasive carcinomas.
Breast Cancer Res Treat. 117:17–24. 2009.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Simícková M, Nekulová M, Pecen L, Cernoch
M, Vagundová M and Pacovský Z: Quantitative determination of
telomerase activity in breast cancer and benign breast diseases.
Neoplasma. 48:267–273. 2001.PubMed/NCBI
|
|
46
|
Nagai N, Oshita T, Murakami J and Ohama K:
Semiquantitative analysis of telomerase activity in cervical cancer
and precancerous lesions. Oncol Rep. 6:325–328. 1999.PubMed/NCBI
|
|
47
|
Liu Y, Fan P, Yang Y, Xu C, Huang Y, Li D,
Qing Q, Sun C and Zhou H: Human papillomavirus and human telomerase
RNA component gene in cervical cancer progression. Sci Rep.
9(15926)2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Zhu Y, Han Y, Tian T, Su P, Jin G, Chen J
and Cao Y: MiR-21-5p, miR-34a, and human telomerase RNA component
as surrogate markers for cervical cancer progression. Pathol Res
Pract. 214:374–379. 2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Ravaioli S, Tumedei MM, Amadori A,
Puccetti M, Chiadini E and Bravaccini S: Role of telomerase in
cervical lesions as prognostic marker: A comparison between
immunohistochemistry and fluorescence in situ hybridization. J Low
Genit Tract Dis. 21:42–46. 2017.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Zhao XY, Cui Y, Jiang SF, Liu KJ, Han HQ,
Liu XS and Li Y: Human telomerase gene and high-risk human
papillomavirus infection are related to cervical intraepithelial
neoplasia. Asian Pac J Cancer Prev. 16:693–697. 2015.PubMed/NCBI View Article : Google Scholar
|
|
51
|
He H, Pan Q, Pan J, Chen Y and Cao L:
Study on the correlation between hTREC and HPV load and cervical
CINI/II/III lesions and cervical cancer. J Clin Lab Anal.
34(e23257)2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Wang SZ, Sun JH, Zhang W, Jin SQ, Wang HP,
Jin YS, Qu P, Liu Y and Li M: Telomerase activity in cervical
intraepithelial neoplasia. Chin Med J (Engl). 117:202–206.
2004.PubMed/NCBI
|
|
53
|
Van Doorslaer K and Burk RD: Association
between hTERT activation by HPV E6 proteins and oncogenic risk.
Virology. 433:216–219. 2012.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Ji W, Lou W, Hong Z, Qiu L and Di W:
Genomic amplification of HPV, h-TERC and c-MYC in liquid-based
cytological specimens for screening of cervical intraepithelial
neoplasia and cancer. Oncol Lett. 17:2099–2106. 2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Alnafakh RAA, Adishesh M, Button L,
Saretzki G and Hapangama DK: Telomerase and telomeres in
endometrial cancer. Front Oncol. 9(344)2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Kyo S, Kanaya T, Takakura M, Tanaka M and
Inoue M: Human telomerase reverse transcriptase as a critical
determinant of telomerase activity in normal and malignant
endometrial tissues. Int J Cancer. 80:60–63. 1999.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Maida Y, Kyo S, Forsyth NR, Takakura M,
Sakaguchi J, Mizumoto Y, Hashimoto M, Nakamura M, Nakao S and Inoue
M: Distinct telomere length regulation in premalignant cervical and
endometrial lesions: Implications for the roles of telomeres in
uterine carcinogenesis. J Pathol. 210:214–223. 2006.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Danescu A, Herrero Gonzalez S, Di
Cristofano A, Mai S and Hombach-Klonisch S: Three-dimensional
nuclear telomere architecture changes during endometrial carcinoma
development. Genes Chromosomes Cancer. 52:716–732. 2013.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Datar RH, Naritoku WY, Li P, Tsao-Wei D,
Groshen S, Taylor CR and Imam SA: Analysis of telomerase activity
in ovarian cystadenomas, low-malignant-potential tumors, and
invasive carcinomas. Gynecol Oncol. 74:338–345. 1999.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Sun PM, Wei LH, Luo MY, Liu G, Wang JL,
Mustea A, Könsgen D, Lichtenegger W and Sehouli J: The telomerase
activity and expression of hTERT gene can serve as indicators in
the anti-cancer treatment of human ovarian cancer. Eur J Obstet
Gynecol Reprod Biol. 130:249–257. 2007.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Pilsworth JA, Cochrane DR, Xia Z, Aubert
G, Färkkilä AEM, Horlings HM, Yanagida S, Yang W, Lim JLP, Wang YK,
et al: TERT promoter mutation in adult granulosa cell tumor of the
ovary. Mod Pathol. 31:1107–1115. 2018.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Gunes C, Wezel F, Southgate J and Bolenz
C: Implications of TERT promoter mutations and telomerase activity
in urothelial carcinogenesis. Nat Rev Urol. 15:386–393.
2018.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Cheng L, Montironi R and Lopez-Beltran A:
TERT promoter mutations occur frequently in urothelial papilloma
and papillary urothelial neoplasm of low malignant potential. Eur
Urol. 71:497–498. 2017.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Cheng L, Davidson DD, Wang M,
Lopez-Beltran A, Montironi R, Wang L, Tan PH, MacLennan GT,
Williamson SR and Zhang S: Telomerase reverse transcriptase (TERT)
promoter mutation analysis of benign, malignant and reactive
urothelial lesions reveals a subpopulation of inverted papilloma
with immortalizing genetic change. Histopathology. 69:107–113.
2016.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Isharwal S, Hu W, Sarungbam J, Chen YB,
Gopalan A, Fine SW, Tickoo SK, Sirintrapun SJ, Jadallah S, Loo FL,
et al: Genomic landscape of inverted urothelial papilloma and
urothelial papilloma of the bladder. J Pathol. 248:260–265.
2019.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Rodriguez Pena MDC, Tregnago AC, Eich ML,
Springer S, Wang Y, Taheri D, Ertoy D, Fujita K, Bezerra SM, Cunha
IW, et al: Spectrum of genetic mutations in de novo PUNLMP of the
urinary bladder. Virchows Arch. 471:761–767. 2017.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Taylor AS, Newell B, Chinnaiyan AM, Hafez
KS, Weizer AZ, Spratt DE, Cameron AP, Al-Ahmadie HA, Gupta S,
Montgomery JS, et al: TERT promoter mutations in keratinizing and
nonkeratinizing squamous metaplasia of the urinary tract. Eur Urol
Open Sci. 35:74–78. 2022.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Weyerer V, Eckstein M, Strissel PL,
Wullweber A, Lange F, Tögel L, Geppert CI, Sikic D, Taubert H, Wach
S, et al: TERT promoter mutation analysis of whole-organ mapping
bladder cancers. Genes. 12(230)2021.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Tu L, Huda N, Grimes BR, Slee RB, Bates
AM, Cheng L and Gilley D: Widespread telomere instability in
prostatic lesions. Mol Carcinog. 55:842–852. 2016.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Graham MK and Meeker A: Telomeres and
telomerase in prostate cancer development and therapy. Nat Rev
Urol. 14:607–619. 2017.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Cheng L, Montironi R, Davidson DD, Wang M,
Lopez-Beltran A and Zhang S: Molecular evidence supporting the
precursor nature of atypical adenomatous hyperplasia of the
prostate. Mol Carcinog. 58:1272–1278. 2019.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Rybicki BA, Sadasivan SM, Chen Y, Loveless
I, Gupta NS, Chitale DA, Williamson SR, Rundle AG and Tang DL: Race
differences in telomere length in benign prostate biopsies and
subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers
Prev. 31:991–998. 2022.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Patel B, Taiwo R, Kim AH and Dunn GP:
TERT, a promoter of CNS malignancies. Neurooncol Adv.
2(vdaa025)2020.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Walsh KM, Wiencke JK, Lachance DH, Wiemels
JL, Molinaro AM, Eckel-Passow JE, Jenkins RB and Wrensch MR:
Telomere maintenance and the etiology of adult glioma. Neuro Oncol.
17:1445–1452. 2015.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Srinivas N, Neittaanmäki N, Heidenreich B,
Rachakonda S, Karppinen TT, Grönroos M, Tani TT, Salmivuori M,
Snellman E, Hemminki K and Kumar R: TERT promoter mutations in
actinic keratosis before and after treatment. Int J Cancer.
146:2932–2934. 2020.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Ventura A, Pellegrini C, Cardelli L, Rocco
T, Ciciarelli V, Peris K and Fargnoli MC: Telomeres and telomerase
in cutaneous squamous cell carcinoma. Int J Mol Sci.
20(1333)2019.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Fullen DR, Zhu W, Thomas D and Su LD:
hTERT expression in melanocytic lesions: An immunohistochemical
study on paraffin-embedded tissue. J Cutan Pathol. 32:680–684.
2005.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Miracco C, Pacenti L, Santopietro R,
Laurini L, Biagioli M and Luzi P: Evaluation of telomerase activity
in cutaneous melanocytic proliferations. Hum Pathol. 31:1018–1021.
2000.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Horn S, Figl A, Rachakonda PS, Fischer C,
Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al:
TERT promoter mutations in familial and sporadic melanoma. Science.
339:959–961. 2013.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Shain AH, Yeh I, Kovalyshyn I, Sriharan A,
Talevich E, Gagnon A, Dummer R, North J, Pincus L, Ruben B, et al:
The genetic evolution of melanoma from precursor lesions. N Engl J
Med. 373:1926–1936. 2015.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Taylor RS, Ramirez RD, Ogoshi M, Chaffins
M, Piatyszek MA and Shay JW: Detection of telomerase activity in
malignant and nonmalignant skin conditions. J Invest Dermatol.
106:759–765. 1996.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Chang KP, Wang CI, Pickering CR, Huang Y,
Tsai CN, Tsang NM, Kao HK, Cheng MH and Myers JN: Prevalence of
promoter mutations in the TERT gene in oral cavity squamous cell
carcinoma. Head Neck. 39:1131–1137. 2017.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Raghunandan BN, Sanjai K, Kumaraswamy J,
Papaiah L, Pandey B and Jyothi BM: Expression of human telomerase
reverse transcriptase protein in oral epithelial dysplasia and oral
squamous cell carcinoma: An immunohistochemical study. J Oral
Maxillofac Pathol. 20:96–101. 2016.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Aida J, Kobayashi T, Saku T, Yamaguchi M,
Shimomura N, Nakamura K, Ishikawa N, Maruyama S, Cheng J, Poon SS,
et al: Short telomeres in an oral precancerous lesion: Q-FISH
analysis of leukoplakia. J Oral Pathol Med. 41:372–378.
2012.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Raju KL, Haragannavar VC, Patil S, Rao RS,
Nagaraj T, Augustine D, Venkatesiah SS and Nambiar S: Expression of
hTERT in oral submucous fibrosis and oral squamous cell
carcinoma-an immunohistochemical analysis. Pathol Oncol Res.
26:1573–1582. 2020.PubMed/NCBI View Article : Google Scholar
|
|
86
|
George JR, Henderson YC, Williams MD,
Roberts DB, Hei H, Lai SY and Clayman GL: Association of TERT
promoter mutation, but not BRAF mutation, with increased mortality
in PTC. J Clin Endocrinol Metab. 100:E1550–E1559. 2015.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Landa I, Ganly I, Chan TA, Mitsutake N,
Matsuse M, Ibrahimpasic T, Ghossein RA and Fagin JA: Frequent
somatic TERT promoter mutations in thyroid cancer: Higher
prevalence in advanced forms of the disease. J Clin Endocrinol
Metab. 98:E1562–E1566. 2013.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Liu R and Xing M: Diagnostic and
prognostic TERT promoter mutations in thyroid fine-needle
aspiration biopsy. Endocr Relat Cancer. 21:825–830. 2014.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Liu T, Wang N, Cao J, Sofiadis A, Dinets
A, Zedenius J, Larsson C and Xu D: The age- and shorter
telomere-dependent TERT promoter mutation in follicular thyroid
cell-derived carcinomas. Oncogene. 33:4978–4984. 2014.PubMed/NCBI View Article : Google Scholar
|
|
90
|
McKelvey BA, Umbricht CB and Zeiger MA:
Telomerase reverse transcriptase (TERT) regulation in thyroid
cancer: A Review. Front Endocrinol (Lausanne).
11(485)2020.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G,
Murugan AK, Guan H, Yu H, Wang Y, et al: TERT promoter mutations
and their association with BRAF V600E mutation and aggressive
clinicopathological characteristics of thyroid cancer. J Clin
Endocrinol Metab. 99:E1130–E1136. 2014.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Nikiforov YE, Carty SE, Chiosea SI, Coyne
C, Duvvuri U, Ferris RL, Gooding WE, Hodak SP, LeBeau SO, Ohori NP,
et al: Highly accurate diagnosis of cancer in thyroid nodules with
follicular neoplasm/suspicious for a follicular neoplasm cytology
by ThyroSeq v2 next-generation sequencing assay. Cancer.
120:3627–3634. 2014.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Qasem E, Murugan AK, Al-Hindi H, Xing M,
Almohanna M, Alswailem M and Alzahrani AS: TERT promoter mutations
in thyroid cancer: A report from a Middle Eastern population.
Endocr Relat Cancer. 22:901–908. 2015.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Su JJ, Hui LZ, Xi CJ and Su GQ:
Correlation analysis of ultrasonic characteristics, pathological
type, and molecular markers of thyroid nodules. Genet Mol Res.
14:9–20. 2015.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Suh YJ, Kwon MJ, Noh HM, Lee HK, Ra YJ and
Kim NY: Limited clinical and diagnostic utility of circulating
tumor DNA detection in patients with early-stage
well-differentiated thyroid cancer: Comparison with benign thyroid
nodules and healthy individuals. Healthcare (Basel).
9(386)2021.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Kachko VA, Vanushko VE, Platonova NM,
Abrosimov AY and Mel'nichenko GA: Somatic mutations in the BRAF,
KRAS, NRAS, EIF1AX, and TERT genes: Diagnostic value in thyroid
neoplasms. Bull Exp Biol Med. 169:669–672. 2020.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Vinagre J, Almeida A, Pópulo H, Batista R,
Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, et al:
Frequency of TERT promoter mutations in human cancers. Nat Commun.
4(2185)2013.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Topf MC, Wang ZX, Tuluc M and Pribitkin
EA: TERT, HRAS, and EIF1AX mutations in a patient with follicular
adenoma. Thyroid. 28:815–817. 2018.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Wang N, Liu T, Sofiadis A, Juhlin CC,
Zedenius J, Höög A, Larsson C and Xu D: TERT promoter mutation as
an early genetic event activating telomerase in follicular thyroid
adenoma (FTA) and atypical FTA. Cancer. 120:2965–2979.
2014.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Boaventura P, Batista R, Pestana A, Reis
M, Mendes A, Eloy C, Sobrinho-Simões M and Soares P: TERT promoter
mutations: A genetic signature of benign and malignant thyroid
tumours occurring in the context of tinea capitis irradiation. Eur
J Endocrinol. 176:49–55. 2017.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Sayiner A and Suren D: Expression of human
telomerase reverse transcriptase (hTERT) in thyroid neoplasms. J
BUON. 23:229–233. 2018.PubMed/NCBI
|
|
102
|
Pestana A, Batista R, Celestino R, Canberk
S, Sobrinho-Simões M and Soares P: Comprehensive assessment of TERT
mRNA expression across a large cohort of benign and malignant
thyroid tumours. Cancers (Basel). 12(1846)2020.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Paulsson JO, Mu N, Shabo I, Wang N,
Zedenius J, Larsson C and Juhlin CC: TERT aberrancies: A screening
tool for malignancy in follicular thyroid tumours. Endocr Relat
Cancer. 25:723–733. 2018.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Seow WJ, Cawthon RM, Purdue MP, Hu W, Gao
YT, Huang WY, Weinstein SJ, Ji BT, Virtamo J, Hosgood HD III, et
al: Telomere length in white blood cell DNA and lung cancer: A
pooled analysis of three prospective cohorts. Cancer Res.
74:4090–4098. 2014.PubMed/NCBI View Article : Google Scholar
|
|
105
|
McNally EJ, Luncsford PJ and Armanios M:
Long telomeres and cancer risk: The price of cellular immortality.
J Clin Invest. 129:3474–3481. 2019.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Gomatou G, Masaoutis C, Vamvakaris I,
Kotteas E, Bouros E, Tzilas V and Bouros D: Differential
immunohistochemical expression of hTERT in lung cancer patients
with and without idiopathic pulmonary fibrosis. Pulmonology:
S2531-0437(22)00002-2, 2022 (Epub ahead of print).
|
|
107
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda
C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL,
Giovanella BC, et al: TERT promoter mutations occur frequently in
gliomas and a subset of tumors derived from cells with low rates of
self-renewal. Proc Natl Acad Sci USA. 110:6021–6026.
2013.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Hosen MI, Sheikh M, Zvereva M, Scelo G,
Forey N, Durand G, Voegele C, Poustchi H, Khoshnia M, Roshandel G,
et al: Urinary TERT promoter mutations are detectable up to 10
years prior to clinical diagnosis of bladder cancer: Evidence from
the Golestan cohort study. EBioMedicine. 53(102643)2020.PubMed/NCBI View Article : Google Scholar
|
